Marvel Biosciences announced that its lead drug candidate, MB-204, demonstrated significant improvements in behavioral and cognitive functions in a Fragile X mouse model during preclinical trials. The drug showed dose-dependent efficacy and durable effects even after treatment stopped, supporting its potential for treating Fragile X syndrome and other autism spectrum disorders. These results add to previous positive findings in Rett syndrome and other ASD models, strengthening the case for advancing MB-204 to clinical trials. The company is also awaiting results from another related preclinical study.
Marvell Technology reported a strong Q2 with revenue up 37% year-over-year and slight beats on revenue and earnings per share. The data center segment grew 46% YoY, driven by demand for AI and custom ASICs, with management forecasting over 60% growth...
Marvell Technology reported a 37% revenue increase in Q2, beating estimates but growing slower than AI chip leaders like Nvidia and Broadcom. Despite management's optimistic guidance for 50% revenue growth in Q3, Marvell's stock valuation remains hig...
In 2026, the VanEck Semiconductor ETF (SMH) returned an impressive 87.86%, largely driven by heavy holdings in NVIDIA and Taiwan Semiconductor. However, three other semiconductor ETFs—Invesco Semiconductors ETF (PSI), Xtrackers Semiconductor Select E...
Marvell Technology reported a 37% year-over-year revenue increase to $2.7 billion in Q2 2026, surpassing analyst expectations. The company’s data center segment saw a 46% revenue rise to $2.2 billion, fueling overall growth. Adjusted earnings per sha...
Marvell Technology is set to report its Q3 earnings on August 27, 2026, with analysts forecasting earnings per share of $0.93 and revenue of $2.72 billion, reflecting a 35% year-over-year increase. This growth is fueled by strong demand in the AI chi...
